Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
M. Cook, Y. Laitman, P. Peterlongo, Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), G. Pita, H. Deiler, J. Brunet, D. Muller, M. Piedmonte, D. Stoppa-Lyonnet, J. Basil, B. Kaufman, J. Cook, B. Arver, G. Pichert, Kathleen Claes(Statistics Belgium), C. T. Oliver, R. Gershoni-Baruch, P. E. Schwartz, Y. Yassin, Marco Montagna(Azienda Ospedale - Università Padova), A. B. Spurdle, A. Viel, B. Versmold, R. Varon-Mateeva, Amanda Ewart Toland, U. G. Froster, Juul T. Wijnen, J. Benítez, C. Casella, N. Lindor, Mark H. Greene, V. Moncoutier, G. Rennert, I. L. Andrulis, Massimo Barile, Fiona Lalloo, U. Hamann, A. C. Spiess, Judith Fricker, D. Gareth Evans(Manchester Academic Health Science Centre), D. G. Cruger, C. Engel, A. Meindl, J. Beesley, AMW van den Ouweland, Olga M. Sinilnikova(Hospices Civils de Lyon), G. Pfeiler, G. C. Rodriguez, Alexandre-Darius Miron
Cited by 2
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
|JNCI Journal of the National Cancer Institute|2013|946